TABLE 1.
Baseline characteristics
| Safety population | PEG monotherapy (N = 24) | PEG+pazopanib (N = 4) | PEG+anti‐PD‐1 a (N = 38) |
|---|---|---|---|
| Age, median, years (range) | 61 (22‐71) | 72 (52‐76) | 66 (32‐77) |
| Sex, n (%) | |||
| Male | 16 (67) | 3 (75) | 27 (71) |
| ECOG PS, n (%) | |||
| 0 | 14 (58) | 2 (50) | 12 (32) |
| 1 | 10 (42) | 2 (50) | 26 (68) |
| TNM stage at initial diagnosis, n (%)b | |||
| Stage I/II | 7 (29) | 0 | 9 (24) |
| Stage III | 5 (21) | 2 (50) | 13 (34) |
| Stage IV | 11 (46) | 2 (50) | 15 (40) |
| IMDC risk groups, n (%) | |||
| Favorable | 2 (8) | 1 (25) | 6 (16) |
| Intermediate | 18 (75) | 1 (25) | 29 (76) |
| Poor | 4 (17) | 2 (50) | 3 (8) |
| Prior therapy (median) | 3 | 1.5 | 2 |
| 0 | 1 (4) | 1 (25) | 6 (16) |
| 1 | 4 (17) | 1 (25) | 10 (26) |
| 2 | 6 (25) | 2 (50) | 9 (24) |
| ≥3 | 13 (54) | 0 | 13 (34) |
| Clear cell histology | 15 (63) | 2 (50) | 25 (66) |
a
Anti‐PD‐1 inhibitors included pembrolizumab and nivolumab. bOne patient in monotherapy and anti‐PD‐1 cohorts had TNM stage classified as “other”. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; n, number of patients in group.